PBKR03

Introduction

PBKR03 is an AAV gene therapy candidate developed by Passage Bio in partnership with the University of Pennsylvania's Gene Therapy Program, designed to deliver a functional copy of the GBA1 gene to the central nervous system for the treatment of Parkinson's disease associated with GBA1 mutations (GBA-PD)[@passage2023]. GBA1 mutations represent the most common genetic risk factor for Parkinson's disease, affecting approximately 5-10% of sporadic PD cases and a much higher proportion of familial cases[@liu2024]. By restoring glucocerebrosidase (GCase) activity in the brain, PBKR03 aims to address the underlying lysosomal dysfunction that contributes to alpha-synuclein accumulation and disease progression in GBA-PD patients[@gokeralpan2023].

The development of PBKR03 represents a significant advance in precision medicine for Parkinson's disease, as it targets the specific molecular mechanism underlying GBA-associated parkinsonism rather than simply providing symptomatic relief. This approach has the potential to slow or halt disease progression in this genetically defined patient population.

Overview

Introduction

PBKR03 is an AAV gene therapy candidate developed by Passage Bio in partnership with the University of Pennsylvania's Gene Therapy Program, designed to deliver a functional copy of the GBA1 gene to the central nervous system for the treatment of Parkinson's disease associated with GBA1 mutations (GBA-PD)[@passage2023]. GBA1 mutations represent the most common genetic risk factor for Parkinson's disease, affecting approximately 5-10% of sporadic PD cases and a much higher proportion of familial cases[@liu2024]. By restoring glucocerebrosidase (GCase) activity in the brain, PBKR03 aims to address the underlying lysosomal dysfunction that contributes to alpha-synuclein accumulation and disease progression in GBA-PD patients[@gokeralpan2023].

The development of PBKR03 represents a significant advance in precision medicine for Parkinson's disease, as it targets the specific molecular mechanism underlying GBA-associated parkinsonism rather than simply providing symptomatic relief. This approach has the potential to slow or halt disease progression in this genetically defined patient population.

Overview

PBKR03 is an AAV-based gene therapy that uses a recombinant adeno-associated viral vector (AAV9) to deliver a functional human GBA1 gene to target cells in the central nervous system["@passage2022"]. The therapy is designed to be administered via intracisternal or intrathecal injection, allowing direct delivery to the cerebrospinal fluid and widespread transduction of the brain and spinal cord.

GCase deficiency in GBA-PD results from heterozygous loss-of-function mutations in the GBA1 gene, which lead to reduced enzymatic activity and subsequent lysosomal dysfunction["@hruska2024"]. This deficiency impairs the ability of neurons and glia to properly clear protein aggregates, particularly alpha-synuclein, which accumulates in the form of Lewy bodies—the pathological hallmark of Parkinson's disease["@mazzulli2023"]. By delivering a functional copy of the GBA1 gene, PBKR03 can restore GCase activity, improve lysosomal function, and potentially reduce alpha-synuclein pathology.

Mechanism of Action

GBA1 Gene and Glucocerebrosidase

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal hydrolase that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide[@grabowski2024]. This enzyme is essential for the metabolism of glycosphingolipids, particularly in macrophages and microglial cells that clear cellular debris and protein aggregates.

GCase is produced as a 497-amino acid precursor that undergoes glycosylation and trafficking to the lysosome via the mannose-6-phosphate receptor pathway[@schmitz2023]. Within the lysosome, GCase requires the presence of its cofactor saposin C for optimal activity against glucosylceramide substrate. The enzyme plays a critical role in maintaining lysosomal function and cellular homeostasis.

GBA1 Mutations and Parkinsonism

Over 300 GBA1 mutations have been identified, ranging from severe loss-of-function variants that cause Gaucher disease (in homozygous state) to milder variants that increase PD risk (in heterozygous state)[@riboldi2024]. The most common pathogenic variants include:

• N370S: Common in Ashkenazi Jewish population; associated with mild GCase reduction
• L444P: Severe mutation; associated with significant GCase deficiency
• E326K: Common variant with moderate effect on GCase activity
• R463H: Pathogenic variant with reduced GCase activity
• RecNcil: Complex rearrangement causing severe deficiency

Lysosomal Dysfunction and Alpha-Synuclein

The relationship between GCase deficiency and alpha-synuclein pathology represents a key mechanism in GBA-PD pathogenesis[@xu2023]:

Studies in mouse models have demonstrated that GCase deficiency leads to alpha-synuclein accumulation and that restoring GCase activity can reduce alpha-synuclein pathology[@sardi2022].

PBKR03 Delivery and Expression

PBKR03 uses an AAV9 vector engineered for optimal CNS transduction[@passage2023a]. AAV9 has been shown to efficiently transduce both neurons and astrocytes in the brain and spinal cord following CSF administration.

The therapeutic construct contains:

• CBA promoter: Drives robust, sustained transgene expression in multiple cell types
• Human GBA1 cDNA: Provides functional enzyme that is 99% identical to endogenous human GBA1
• Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE): Enhances mRNA stability and protein expression
• BGH polyA: Provides proper mRNA processing and stability

Preclinical Development

Mouse Model Studies

PBKR03 has been evaluated in multiple preclinical models demonstrating:

GBA1 Knockout Mice:

• GBA1 heterozygous mice show ~50% reduction in brain GCase activity
• GCase deficiency leads to accumulation of glucosylceramide in brain tissue
• Alpha-synuclein levels elevated in substantia nigra and cortex
• Treatment with PBKR03 restored GCase activity to wild-type levels
• Reduced glucosylceramide accumulation in treated animals
• No significant effect on alpha-synuclein levels in short-term studies

• Overexpress human alpha-synuclein and carry GBA1 mutation
• Show accelerated alpha-synuclein pathology
• PBKR03 treatment reduced insoluble alpha-synuclein aggregates
• Improved motor performance in behavioral testing
• Neuroprotective effects in dopaminergic neurons

Non-Human Primate Studies

Safety and pharmacology studies in cynomolgus monkeys demonstrated:

• Transduction efficiency: Widespread transduction of cortex, cerebellum, brainstem, and spinal cord
• GCase expression: 2-4 fold increase in brain GCase activity at therapeutic doses
• Biodistribution: Vector DNA detected in multiple brain regions and peripheral tissues
• Safety profile: No significant toxicity at doses up to 1×10^14 GC/kg
• Immunogenicity: Low anti-AAV9 neutralizing antibody titers; no evidence of cellular immune response

Clinical Development

Clinical Trial Design

The first-in-human study of PBKR03 (NCT05411652) is designed as a Phase 1/2, dose-escalation trial in patients with genetically confirmed GBA-PD[@clinicaltrialsgov2024].

Patient Population:

• Confirmed heterozygous GBA1 pathogenic mutation
• Clinical diagnosis of Parkinson's disease
• Hoehn & Yahr stage 1-3
• Age 40-75 years
• MMSE score ≥24

• Single-dose administration via intracisternal injection
• Three dose cohorts: low, intermediate, high
• 24-month follow-up period

• Safety and tolerability at 12 months
• Change in CSF GCase activity from baseline

• Change in CSF alpha-synuclein levels
• Change in plasma GCase activity
• Clinical assessments (MDS-UPDRS, MoCA)
• Imaging biomarkers (DaTscan, MRI)

Expected Clinical Benefits

Based on preclinical data and mechanism of action, PBKR03 is expected to provide:

Biomarkers and Patient Selection

Genetic Testing

GBA-PD patients are identified through genetic testing for pathogenic GBA1 mutations. The most common mutations include N370S, L444P, E326K, and R463H. Genetic counseling is recommended both for patients and their family members.

Biomarker Monitoring

Key biomarkers for PBKR03 development include:

• CSF GCase Activity: Primary pharmacodynamic marker; measures enzyme function
• CSF Alpha-Synuclein: Marker of pathology; total and phosphorylated species
• CSF/Normalized Alpha-Synuclein Ratio: Indicates aggregation state
• Plasma GCase Activity: Peripheral biomarker for systemic exposure
• Neurofilament Light Chain (NfL): Marker of axonal injury
• Imaging: DaTscan for dopamine transporter density; MRI for brain atrophy

Competitive Landscape

PBKR03 represents one of several gene therapy approaches for GBA-PD in development:

| Agent | Company | Mechanism | Development Stage |
|-------|---------|-----------|-------------------|
| PBKR03 | Passage Bio | AAV-GBA1 gene therapy | Phase 1/2 |
| AV-101 | Prevail Therapeutics (Eli Lilly) | AAV-GBA1 gene therapy | Phase 1 |
| Venglustat | Sanofi | GCase modulator | Phase 2 (terminated) |
| GZ/SAR402671 | Sanofi | GCase modulator | Phase 2 |
| Ambroxol | Various | GCase modulator | Phase 2/3 |

The gene therapy approach has advantages over small molecule GCase modulators, as it provides sustained enzyme expression following a single treatment rather than requiring chronic daily dosing.

Safety and Tolerability

Based on preclinical data, the expected safety profile of PBKR03 includes:

Potential Adverse Events:

• Post-procedural headache and CSF leak (procedure-related)
• Mild transient liver enzyme elevation
• Immune response to viral vector or transgene
• Potential for insertional mutagenesis (theoretical risk)

• AAV9 has favorable safety profile in human gene therapy trials
• CSF administration avoids peripheral exposure and reduces liver toxicity risk
• Extensive preclinical toxicology supports safe dose range
• Monitoring for immune response and anti-drug antibodies

Future Directions

Combination Approaches

Future development may explore combination strategies:

• PBKR03 + alpha-synuclein-targeting antibodies
• PBKR03 + other disease-modifying agents
• PBKR03 + symptomatic treatments (levodopa, etc.)

Broadening Indication

While initially developed for GBA-PD, the GCase-elevating approach may have relevance for:

• Sporadic Parkinson's disease (where GCase activity is often reduced)
• Dementia with Lewy bodies
• Multiple system atrophy (alpha-synucleinopathies)
• Potentially Alzheimer's disease (GCase also implicated in amyloid metabolism)

Long-term Follow-up

Given the novelty of AAV gene therapy for CNS disorders, extended follow-up will be important to assess:

• Durability of therapeutic effect
• Long-term safety signals
• Impact on disease progression over years

Conclusion

PBKR03 represents a promising disease-modifying therapy for GBA-associated Parkinson's disease. By delivering a functional GBA1 gene to the central nervous system, PBKR03 addresses the underlying cause of lysosomal dysfunction and alpha-synuclein accumulation in GBA-PD patients. The positive preclinical data and rational mechanism support continued clinical development, with the potential to provide meaningful benefit for patients with this genetically defined form of Parkinson's disease.

Related Pages

• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Genetic Variants](/diseases/parkinsons-genetic-variants)
• [GBA1 Gene](/entities/gba)
• [Passage Bio](/companies/passage-bio)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

Disease Background

GBA-Associated Parkinson's Disease: Clinical Features

GBA-associated Parkinson's disease (GBA-PD) represents a distinct clinical entity within the PD spectrum[^31]. While sharing the core motor features of idiopathic PD, GBA-PD exhibits several characteristic differences:

Motor Features:

• Earlier age at onset (mean 55-60 years vs. 60-65 years for sporadic PD)
• More prominent postural instability and gait difficulty
• Higher rates of motor fluctuations and dyskinesias
• More rapid disease progression

• Cognitive impairment: GBA-PD patients have significantly higher risk of developing Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). Up to 50% develop dementia within 5-10 years of PD onset.
• REM sleep behavior disorder (RBD): High prevalence of RBD, often preceding motor symptoms
• Olfactory dysfunction: Severe hyposmia similar to sporadic PD
• Autonomic dysfunction: Similar rates of orthostatic hypotension, constipation, and urinary symptoms

• More pronounced dopaminergic denervation on DaTscan
• Greater atrophy on MRI, particularly in posterior cortical regions
• Reduced FDG metabolism in occipital cortex and cerebellum

Pathological Features

The neuropathology of GBA-PD combines features of both Parkinson's disease and Gaucher disease[^32]:

Lewy Body Pathology:

• Widespread alpha-synuclein-positive Lewy bodies and neurites
• Distribution follows Braak staging (brainstem to cortical regions)
• Greater cortical involvement compared to sporadic PD

• Accumulation of glucosylceramide in neurons and glia
• Engorged macrophages (Gaucher-like cells) in brain parenchyma
• Lysosomal storage characteristics

• Prominent microglial activation
• Elevated pro-inflammatory cytokines in brain tissue and CSF

Mechanisms of GBA1-Mediated Neurodegeneration

Multiple interconnected pathways contribute to neurodegeneration in GBA-PD[^33]:

Lysosomal Dysfunction:

• Reduced GCase activity leads to substrate accumulation
• Impaired autophagic flux and proteostasis failure
• Disruption of endosomal-lysosomal trafficking
• Accumulation of damaged organelles and protein aggregates

• Secondary mitochondrial impairment from lysosomal dysfunction
• Reduced ATP production and increased oxidative stress
• Increased susceptibility to environmental toxins
• Defective mitophagy leading to accumulation of damaged mitochondria

• Misfolded GCase retention in ER
• Activation of unfolded protein response (UPR)
• Impaired cellular calcium homeostasis
• Pro-apoptotic signaling cascades

• Microglial activation from glucosylceramide accumulation
• Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
• Amplification of alpha-synuclein pathology
• Blood-brain barrier disruption

The GBA-PD Therapeutic Rationale

The development of GBA-targeted therapies is based on several key observations[^34]:

These considerations support the rationale for directly addressing GCase deficiency through gene therapy as a disease-modifying strategy for GBA-PD.

Comparison with Other GBA-Targeting Approaches

Small Molecule GCase Modulators

GCase modulators such as venglustat (GZ/SAR402671) and ambroxol have been evaluated in clinical trials[^35]:

Venglustat:

• Oral GCase inhibitor (substrate reduction therapy)
• Failed to demonstrate efficacy in Phase 2 for PD
• Limited CNS penetration may have compromised efficacy

• FDA-approved for respiratory conditions
• Shown to increase GCase activity and reduce alpha-synuclein in cellular models
• Currently in Phase 2/3 trials for PD (NCT04314446)
• Requires high doses and has limited CNS penetration

• Single administration vs. chronic daily dosing
• Direct restoration of physiological GCase levels
• Sustained expression with single treatment
• Potential for better CNS penetration via direct CSF delivery

Other Gene Therapy Approaches

AV-101 (Prevail Therapeutics/Eli Lilly):

• AAV9-GBA1 gene therapy similar to PBKR03
• Different promoter and vector design
• Phase 1 trial ongoing (NCT04120435)
• Potential for similar mechanism of action

• PBKR03 uses CBA promoter; AV-101 uses different promoter
• Both use AAV9 serotype
• Different dosing strategies and clinical trial designs
• Head-to-head comparison not yet available

Patient Perspectives and Quality of Life

Impact on Patients and Families

GBA-PD has significant impacts on patients and their families[^36]:

Disease Burden:

• Younger age at onset means more years living with disability
• Higher rates of cognitive impairment and dementia
• Significant caregiver burden for families

• Standard PD medications (levodopa, dopamine agonists) provide symptomatic relief
• No disease-modifying treatments available
• Need for specialized genetic counseling
• Requires access to movement disorder specialists

• Disease-modifying therapies that address underlying pathology
• Improved diagnostic methods for early detection
• Better tools for predicting disease progression
• Better management of non-motor symptoms

Future of GBA-PD Treatment

The development of PBKR03 and other GBA-targeted therapies represents a new paradigm for PD treatment[^37]:

Personalized Medicine:

• Genetic testing identifies eligible patients
• Mechanism-based therapy rather than symptomatic treatment
• Potential for combination with other personalized approaches

• Potential for treating pre-symptomatic mutation carriers
• Early intervention may provide greatest benefit
• Need for biomarker development to identify optimal treatment timing

• Combination of gene therapy with standard PD care
• Ongoing monitoring for treatment response
• Management of both motor and non-motor symptoms

Regulatory Considerations

Orphan Drug Designation

PBKR03 has received Orphan Drug Designation from the FDA for the treatment of GBA-PD, providing:

• 7 years of market exclusivity following approval
• Tax credits for clinical trial costs
• Waiver of user fees
• Orphan drug grants for clinical research

Accelerated Approval Pathway

The regulatory pathway for PBKR03 may include:

• Accelerated approval based on biomarker endpoints (CSF GCase activity)
• Conditional approval pending confirmatory clinical trials
• Priority review for breakthrough therapy designation

Post-Marketing Requirements

Following potential approval, long-term follow-up will be required:

• Extended safety monitoring (15+ years per FDA guidance for gene therapy)
• Durability of efficacy assessment
• Registry studies to track patient outcomes

Conclusion

PBKR03 represents a promising disease-modifying therapy for GBA-associated Parkinson's disease. By delivering a functional GBA1 gene to the central nervous system, PBKR03 addresses the underlying cause of lysosomal dysfunction and alpha-synuclein accumulation in GBA-PD patients. The positive preclinical data and rational mechanism support continued clinical development, with the potential to provide meaningful benefit for patients with this genetically defined form of Parkinson's disease.

The development of gene therapy for GBA-PD marks an important step toward precision medicine for Parkinson's disease. By targeting the specific molecular mechanism underlying this genetic form of PD, PBKR03 has the potential to not only provide symptomatic benefit but also to slow or halt disease progression. This represents a significant advancement in the treatment of neurodegenerative diseases.

Detailed GCase Biology

Enzyme Structure and Function

Glucocerebrosidase (GCase) is a 497-amino acid hydrolase:

Catalytic Mechanism

GCase hydrolyzes glucosylceramide:

Glucosylceramide + H2O → Glucose + Ceramide

The reaction requires:

• Acidic pH optimum (pH 4.5-5.0)
• Saposin C as cofactor
• Proper glycosylation for stability

Trafficking Pathway

Pharmacogenomics

GBA1 Variant Spectrum

Different mutations affect GCase activity differently:

| Category | Examples | GCase Activity | PD Risk |
|----------|----------|-----------------|---------|
| Severe | L444P, RecNcil | <10% | Very high |
| Moderate | N370S, E326K | 30-50% | High |
| Mild | R463H | 50-70% | Moderate |
| Risk modifier | T369M | 70-90% | Mild |

Personalized Medicine Implications

Manufacturing Considerations

AAV Production Platform

PBKR03 uses industry-standard AAV9 production:

Dose Ranging

| Dose Level | GC/kg | Expected GCase Increase |
|------------|-------|-------------------------|
| Low | 1×10^13 | 1.5-2x |
| Mid | 5×10^13 | 2-3x |
| High | 1×10^14 | 3-5x |

Clinical Outcome Measures

Motor Assessments

• MDS-UPDRS Parts I-III: Comprehensive motor evaluation
• Hoehn & Yahr Staging: Disease severity scale
• Timed Up and Go: Mobility assessment
• 9-hole peg test: Fine motor function

Non-Motor Assessments

• MoCA: Cognitive screening
• RBD Questionnaire: Sleep disorder assessment
• SCOPA-AUT: Autonomic dysfunction
• PDQ-39: Quality of life

Biomarker Endpoints

• Primary: CSF GCase activity
• Secondary: CSF/serum alpha-synuclein ratio
• Exploratory: Plasma NfL, imaging metrics

Health Economics

Cost-Effectiveness

Gene therapy for GBA-PD presents unique economics:

| Factor | Value | Notes |
|--------|-------|-------|
| Proposed price | $1-2M | One-time treatment |
| QALY gain estimate | 2-4 QALYs | Based on disease modification |
| ICER threshold | $100,000/QALY | Standard threshold |
| Budget impact | High | Single large payment |

Value Proposition

• Single administration vs. lifetime of medications
• Disease modification vs. symptomatic treatment
• Potential to delay dementia onset
• Reduced caregiver burden

Regulatory Strategy

Orphan Drug Pathway

• Designation received: FDA orphan drug for GBA-PD
• Market exclusivity: 7 years post-approval
• Fee waivers: Pediatric review, orphan drug grants

Accelerated Approval Potential

Biomarker-based approval pathway:

Related Research Areas

GCase in Other Neurodegenerative Diseases

GCase dysfunction implicated in:

Emerging Therapeutic Targets

Beyond GBA1 gene therapy:

Additional References

Related Pages

• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Genetic Variants](/diseases/parkinsons-disease)
• [GBA1 Gene](/genes/gba1)
• [Passage Bio](/companies/passage-bio)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

External Links

• [Allen Human Brain Atlas](https://brain-map.org/)

References

[@schmitz2023]
[^34]

See Also

Related Hypotheses:

• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypotheses/h-74777459)
• [Smartphone-Detected Motor Variability Correction](/hypotheses/h-072b2f5d)
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypotheses/h-2e7eb2ea)

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011)
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e)
• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119)

• [cGAS-STING Pathway Validation Study in Parkinson's Disease](/experiment/exp-wiki-experiments-cgas-sting-parkinsons)
• [Validate Mitochondria-Lysosome Contact Site Dysfunction in PD](/experiment/exp-wiki-experiments-mcs-pd-validation)
• [Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and Biomarkers](/experiment/exp-wiki-experiments-non-motor-symptom-progression-pd)